---
title: "ZHIYANG INNOVATION's net profit for the year 2024 is 50.1748 million yuan, a year-on-year increase of 20.81%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/229726385.md"
description: "ZHIYANG INNOVATION released its 2024 annual performance report, with total operating revenue of 972 million yuan, a year-on-year increase of 21.74%; net profit of 50.1748 million yuan, a year-on-year increase of 20.81%; net profit excluding non-recurring gains and losses of 37.3798 million yuan, a year-on-year increase of 36.11%; basic earnings per share of 0.33 yuan. The company has increased its investment in research and development, with continuous growth in performance in the fields of electricity, water conservancy, and rail transportation"
datetime: "2025-02-26T09:31:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/229726385.md)
  - [en](https://longbridge.com/en/news/229726385.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/229726385.md)
generator: "portal-rs"
---

# ZHIYANG INNOVATION's net profit for the year 2024 is 50.1748 million yuan, a year-on-year increase of 20.81%

According to the Zhitong Finance APP, ZHIYANG INNOVATION (688191.SH) released its 2024 annual performance preliminary report. The company's total operating revenue for 2024 was 972 million yuan, a year-on-year increase of 21.74%; the net profit attributable to the parent company's owners was 50.1748 million yuan, a year-on-year increase of 20.81%; the net profit attributable to the parent company's owners after deducting non-recurring gains and losses was 37.3798 million yuan, a year-on-year increase of 36.11%; basic earnings per share were 0.33 yuan.

During the reporting period, the company continued to increase investment in research and development and new business areas. The company's business in the power sector experienced sustained and stable growth, while the performance in the water conservancy and rail transit sectors achieved rapid growth

### Related Stocks

- [688191.CN](https://longbridge.com/en/quote/688191.CN.md)

## Related News & Research

- [ANALYSIS-Investors heartened by Warsh inflation talk, still uncertain about Fed action](https://longbridge.com/en/news/297468486.md)
- [12:09 ETHaier Biomedical präsentiert automatisierte Biolagerung und vernetzte Pharma-Lösungen auf der ISPE Singapore 2026](https://longbridge.com/en/news/297810393.md)
- [Biocytogen licenses fully human VHH antibody to Qilu Pharma in non-exclusive deal](https://longbridge.com/en/news/297781804.md)
- [FACTBOX-Wall Street divided on Fed policy path as Barclays joins hawkish camp](https://longbridge.com/en/news/297512438.md)
- [REG - AstraZeneca PLC - AstraZeneca completes agreement for Zegfrovy](https://longbridge.com/en/news/297603898.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**